Legislative sessions across the U.S. have got off to a lively start this year, with dozens of new psychedelics-related bills introduced and several efforts from the previous year reignited as legislatures reconvened.

Ibogaine research programs and multi-state consortia efforts are featuring prominently in the flurry of bills introduced this month, with an ibogaine research bill making a swift passage through the Mississippi House in a near-unanimous vote. Elsewhere, psilocybin rescheduling trigger law bills are again appearing in several states, as Compass Pathways aims to pre-emptively reduce rescheduling friction.

While earlier years featured bills envisaging ambitious, permanent modifications to psychedelics access, 2026 appears to have a higher density of time-bounded pilot programs.

Indeed, the most consequential state-level policy development in January came from one such pilot program, as outgoing New Jersey Governor Phil Murphy signed SB 2283 into law, establishing a two-year psilocybin pilot across three hospitals in the state. The bill allocates $6 million in funding, split evenly between the hospitals, and was first introduced in January 2024.

January also saw the introduction of a new bill at the federal level, dubbed the Expanding Veterans’ Access to Emerging Treatments Act. We provide a deeper dive into that bill in our Federal section.

Below, we provide a state-by-state round-up of psychedelics-related bill activity in January 2026…